| • |
NSAID-Induced GI Toxicity
This program explores critical issues pertaining to GI side-effects of NSAIDs and strategies to minimize them. Using a case-based approach, renowned experts respond to clinically relevant questions such as: Who is at risk and what is the risk? Who needs these medications and what is their benefit over non - NSAIDs? Can the risk of NSAID-induced GI toxicity be modified? The discussion builds upon a recent AGA Institute NSAID consensus statement developed by a multidisciplinary panel that will be published in Clinical Gastroenterology and Hepatology.
Supported through an educational grant from TAP Pharmaceutical Products Inc.
|
| • |
Updates in the Management of Chronic Constipation
Constipation affects at least 10 percent of the general U.S. population (25 percent of the elderly) and accounts for more than 2.5 million physician visits each year. Management of chronic constipation (constipation lasting more than 12 months) requires education on defined diagnostic criteria, proper patient work-up and available treatment options. As constipation is the most frequent reason for referral to a gastroenterologist, during this program, three renowned experts discuss updates in the management of chronic constipation using a case-based approach to explore key clinical questions relating to disease and patient management.
Supported through an educational grant from Sucampo-Takeda.
|
| • |
Effective Management of Ulcerative Colitis
Ulcerative colitis (UC) is a treatable condition that affects more than 500,000 Americans. Most UC cases are mild to moderate and can be managed medically. Until recently, management options heavily relied on oral medications that require frequent daily doses or the application of topical agents, which many patients find inconvenient. The availability of newer formulations and development of new delivery technology might improve management of UC. During this program, three renowned experts discuss the effective management of ulcerative colitis using a case-based approach to explore key clinical questions relating to disease management.
Supported through an educational grant from Shire Pharmaceuticals.
|
| |
| Other Available AGA CME Programs |
 |
| • |
Expired AGA CME Café Programs |
|
| • |
AGA Conversations |
|
